المؤلفون: Akinori Hara¹ hara-akinori@med.kanazawa-u.ac.jp, Ken-ei Sada², Takashi Wada³, Koichi Amano⁴, Hiroaki Dobashi⁵, Tatsuya Atsumi⁶, Takahiko Sugihara⁷, Kouichi Hirayama⁸, Shogo Banno⁹, Yohko Murakawa¹⁰, Midori Hasegawa¹¹, Kunihiro Yamagata¹², Yoshihiro Arimura^13,14, Hirofumi Makino¹⁵, Masayoshi Harigai¹⁶

المصدر: Modern Rheumatology. Mar2024, Vol. 34 Issue 2, p382-390. 9p.

مصطلحات موضوعية: *CHRONIC kidney failure, *VASCULITIS, *LONGITUDINAL method, *REMISSION induction, *JAPANESE people

مصطلحات جغرافية: JAPAN

مستخلص: Objectives: This study elucidated the prognosis and risk factors associated with damage accrual during long-term remission maintenance therapy for patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV). Methods: We obtained data from 120 patients registered in a nationwide prospective cohort study on remission induction therapy in Japanese patients with AAV and rapidly progressive glomerulonephritis (RemIT-JAV-RPGN), who achieved remission at 24 months after treatment initiation and were followed up for additional 24 months. The primary outcome was the vasculitis damage index (VDI) score at Month 48, and the secondary outcome included risk factors associated with increased total VDI at Month 48. Results: The understudied patients comprised 52 men and 68 women aged 68 ± 13 years. Between Months 25 and 48, the patients' survival rate was 95% (114/120). End-stage renal disease developed in seven patients by Month 48, and 64 cases had increased VDI. The multivariable analysis results revealed that oral prednisolone (PSL) doses at Month 24 were associated with damage accrual between Months 24 and 48. Conclusions: VDI accrual was observed in more than half of patients with AAV during maintenance therapy, and increased VDI scores were associated with oral PSL doses 24 months after initiating remission induction therapy in Japan. [ABSTRACT FROM AUTHOR]

المؤلفون: Akinori Hara, Ken-ei Sada, Takashi Wada, Koichi Amano, Hiroaki Dobashi, Tatsuya Atsumi, Takahiko Sugihara, Kouichi Hirayama, Shogo Banno, Yohko Murakawa, Midori Hasegawa, Kunihiro Yamagata, Yoshihiro Arimura, Hirofumi Makino, Masayoshi Harigai

المصدر: Modern Rheumatology.

مصطلحات موضوعية: Rheumatology

الوصف: ObjectivesThis study elucidated the prognosis and risk factors associated with damage accrual during long-term remission maintenance therapy for patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).MethodsWe obtained data from 120 patients registered in a nationwide prospective cohort study on remission induction therapy in Japanese patients with AAV and rapidly progressive glomerulonephritis (RemIT-JAV-RPGN), who achieved remission at 24 months after treatment initiation and were followed up for additional 24 months. The primary outcome was the vasculitis damage index (VDI) score at Month 48, and the secondary outcome included risk factors associated with increased total VDI at Month 48.ResultsThe understudied patients comprised 52 men and 68 women aged 68 ± 13 years. Between Months 25 and 48, the patients’ survival rate was 95% (114/120). End-stage renal disease developed in seven patients by Month 48, and 64 cases had increased VDI. The multivariable analysis results revealed that oral prednisolone (PSL) doses at Month 24 were associated with damage accrual between Months 24 and 48.ConclusionsVDI accrual was observed in more than half of patients with AAV during maintenance therapy, and increased VDI scores were associated with oral PSL doses 24 months after initiating remission induction therapy in Japan.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::9ad08497aef7bb91d4f661118e342326Test
https://doi.org/10.1093/mr/road029Test

المؤلفون: Ken-Ei Sada, Tetsuya Horita, Eishu Nango, Kenji Nagasaka, Kunihiro Yamagata, Takeo Nakayama, Soko Kawashima, Taichi Hayashi, Yoshihiro Arimura, Taio Naniwa, Yasuhiro Katsumata, Noboru Hagino, Masayoshi Harigai, Akinori Hara, Michi Tsutsumino, Mitsuyo Itabashi, Satoshi Ito, Sakae Homma

المصدر: Modern rheumatology. 29(1)

مصطلحات موضوعية: medicine.medical_specialty, Advisory Committees, ANCA-Associated Vasculitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, urologic and male genital diseases, 03 medical and health sciences, 0302 clinical medicine, Government Agencies, Rheumatology, Japan, immune system diseases, Internal medicine, medicine, Humans, cardiovascular diseases, 030212 general & internal medicine, skin and connective tissue diseases, Anti-neutrophil cytoplasmic antibody, Randomized Controlled Trials as Topic, 030203 arthritis & rheumatology, business.industry, Guideline, medicine.disease, respiratory tract diseases, Clinical Practice, Meta-analysis, Practice Guidelines as Topic, Granulomatosis with polyangiitis, Microscopic polyangiitis, business, Vasculitis, Immunosuppressive Agents

الوصف: To provide evidence for the revision of clinical practice guideline (CPG) for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) by the Japan Research Committee for Intractable Vasculitis.PubMed, CENTRAL, and the Japan Medical Abstracts Society were searched for articles published between January 1994 and January 2015 to conduct systematic review (SR), and the quality of evidence was assessed with GRADE approach.Nine randomized controlled trials (RCTs) and two non-RCTs were adopted for remission induction therapy, three RCTs and two non-RCTs for plasma exchange, and five RCTs and one non-RCT for remission maintenance therapy. A significant difference was found in efficacy and safety for the following comparisons. In the non-RCT adopted for remission induction therapy, glucocorticoid (GC) + cyclophosphamide (CY) was significantly superior to GC monotherapy regarding remission. GC + intravenous CY for remission induction therapy was superior to GC + oral CY regarding death at one year, serious adverse events, and serious infection. Concomitant use of plasma exchange for remission induction therapy of AAV with severe renal dysfunction reduced risk of end-stage renal disease versus non-users at month 3.This SR provided necessary evidence for developing CPG for the management of ANCA-associated vasculitis.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::055ad602497fffb85db9385ab5832906Test
https://pubmed.ncbi.nlm.nih.gov/29996690Test

المؤلفون: Tadashi Toyama, Akinori Hara, Toshiya Okumura, Takashi Wada, Akihiro Sagara, Kengo Furuichi, Kiyoki Kitagawa, Yoshio Sakai, Shuichi Kaneko, Shinji Kitajima

المصدر: Modern Rheumatology. 22:610-615

مصطلحات موضوعية: Adult, medicine.medical_specialty, Pathology, Gastroenterology, Dermatomyositis, Scleroderma, Autoimmune Diseases, Diagnosis, Differential, Remission induction, Fatal Outcome, Rheumatology, Internal medicine, Colostomy, medicine, Humans, Lupus Erythematosus, Systemic, skin and connective tissue diseases, Pneumatosis intestinalis, Pneumatosis Cystoides Intestinalis, Gastrointestinal tract, Scleroderma, Systemic, Lupus erythematosus, Cefotiam, business.industry, Remission Induction, Middle Aged, medicine.disease, Combined Modality Therapy, Anti-Bacterial Agents, Female, Nutrition Therapy, medicine.symptom, Tomography, X-Ray Computed, business, Rare disease

الوصف: Pneumatosis intestinalis (PI) is a comparatively rare disease characterized by the presence of intramural gas in the gastrointestinal tract. PI is known to be associated with several clinical conditions, such as pulmonary diseases, gastrointestinal diseases, and traumatic injury, as well as autoimmune disorders. In particular, PI is commonly seen in systemic sclerosis (SSc) but rarely in systemic lupus erythematosus and dermatomyositis (DM). In this report, we present three cases of PI presenting in autoimmune diseases, including DM, Sjögren's syndrome, and limited SSc, and further discuss its background characteristics.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c49424bb8550e22a84553c5c169acef8Test
https://doi.org/10.3109/s10165-011-0551-3Test

المؤلفون: Seiko Kitamura, Shuichi Kaneko, Kengo Furuichi, Miki Tomokage, Mitsutoshi Nakada, Takashi Wada, Akinori Hara, Norihiko Sakai, Kiyoki Kitagawa, Yoh Zen, Shinji Kitajima

المصدر: Modern Rheumatology. 20(5):506-510

مصطلحات موضوعية: Male, medicine.medical_specialty, Pathology, Necrosis, Sarcoidosis, Necrotizing sarcoid granuloma, Radiography, Peptidyl-Dipeptidase A, Neurosarcoidosis, Young Adult, Rheumatology, Central Nervous System Diseases, hemic and lymphatic diseases, medicine, Humans, Pathological, Epilepsy, Granuloma, biology, medicine.diagnostic_test, business.industry, Brain, Angiotensin-converting enzyme, Magnetic resonance imaging, medicine.disease, Magnetic Resonance Imaging, biology.protein, Immunohistochemistry, Radiography, Thoracic, Lymph Nodes, Radiology, Neurosurgery, medicine.symptom, Tomography, X-Ray Computed, business

الوصف: 金沢大学医薬保健研究域医学系
We described a case of neurosarcoidosis with necrotizing sarcoid granulomatosis in a 22-year-old man. Contrast-enhanced brain computed tomography scan and magnetic resonance imaging showed intracerebral multiple nodular lesions. Noncaseating and partial necrotizing granulomas were detected in the specimen resected by neurosurgery. In addition, immunohistochemical examination revealed the expression of angiotensin-converting enzyme in necrotizing granuloma. Thus, these findings were consistent with neurosarcoidosis. Clinical and pathological presentation, immunological features, and treatment modalities of neurosarcoidosis are discussed. © 2010 Japan College of Rheumatology.
This is the pre-peer reviewed version of the following article: [Full cite], which has been published in final form at [link to final article].

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04a8f81273375344f18ffe2dd30967acTest
http://hdl.handle.net/2297/25880Test

المؤلفون: Kenji Nagasaka, Masayoshi Harigai, Noboru Hagino, Akinori Hara, Tetsuya Horita, Taichi Hayashi, Mitsuyo Itabashi, Satoshi Ito, Yasuhiro Katsumata, Soko Kawashima, Taio Naniwa, Ken-Ei Sada, Eishu Nango, Takeo Nakayama, Michi Tsutsumino, Kunihiro Yamagata, Sakae Homma, Yoshihiro Arimura

المصدر: Modern Rheumatology; 2019, Vol. 29 Issue 1, p119-129, 11p

مصطلحات موضوعية: VASCULITIS, ANTINEUTROPHIL cytoplasmic antibodies, SYSTEMATIC reviews, CYCLOPHOSPHAMIDE, ADVERSE health care events, PLASMA exchange (Therapeutics)

مستخلص: Objectives: To provide evidence for the revision of clinical practice guideline (CPG) for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) by the Japan Research Committee for Intractable Vasculitis. Methods: PubMed, CENTRAL, and the Japan Medical Abstracts Society were searched for articles published between January 1994 and January 2015 to conduct systematic review (SR), and the quality of evidence was assessed with GRADE approach. Results: Nine randomized controlled trials (RCTs) and two non-RCTs were adopted for remission induction therapy, three RCTs and two non-RCTs for plasma exchange, and five RCTs and one non-RCT for remission maintenance therapy. A significant difference was found in efficacy and safety for the following comparisons. In the non-RCT adopted for remission induction therapy, glucocorticoid (GC)þcyclophosphamide (CY) was significantly superior to GC monotherapy regarding remission. GCþintravenous CY for remission induction therapy was superior to GCþoral CY regarding death at one year, serious adverse events, and serious infection. Concomitant use of plasma exchange for remission induction therapy of AAV with severe renal dysfunction reduced risk of end-stage renal disease versus non-users at month 3. Conclusion: This SR provided necessary evidence for developing CPG for the management of ANCAassociated vasculitis. [ABSTRACT FROM AUTHOR]

: Copyright of Modern Rheumatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)